Drug Discovery World

DECEMBER 20, 2023

The company has 155 investigators who perform trials in around 20 therapeutic areas, including infectious disease, neurology, endocrinology, oncology, cardiology, dermatology and vaccines.

Clinical Research 52

Clinical Research Research Cardiology Dermatology 52

pharmaphorum

JANUARY 5, 2021

An IQVIA survey to Neurology, Cardiology, Rheumatology, Dermatology and Ophthalmologists in June 2020 across the lead five European countries showed an average of 30% of patients either “no shows” or still waiting for treatment that was delayed.

Sales 104

Sales Marketing Production Vaccination 104

The Pharma Data

SEPTEMBER 15, 2020

The company announced the initiation of its Phase 1b clinical trial to evaluate the safety of a novel investigational therapeutic for COVID-19, PF-07304814. Based on current infection rates, the companies continue to expect that a conclusive readout on efficacy is likely by the end of October. Protease Inhibitor Program. and -50.4%

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

APRIL 26, 2021

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. The canakinumab development program continues, with two Ph3 non-small cell lung cancer clinical trials ongoing in first-line and adjuvant setting. Adakveo sales reached USD 37 million.

Sales 40

Sales Medicine Production Manufacturing 40

XTalks

AUGUST 2, 2023

Clinical trials have shown that the vaccine is 90 percent effective in preventing shingles for individuals aged 50 and over. At present, the company has approximately 45 new drugs in Phase II or Phase III clinical trials, or awaiting approval from regulatory authorities in the US, Europe or Japan. billion ($3.65

Sales 98

Sales Manufacturing FDA Approval Life Science 98